HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Balasubramaniam, A. Articles by Sheriff, S. Search for Related Content PubMed PubMed Citation Articles by Balasubramaniam, A. Articles by Sheriff, S. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 265, Issue 25, 14724-14727, Sep, 1990

Neuropeptide Y (18-36) is a competitive antagonist of neuropeptide Y in rat cardiac ventricular membranes

A Balasubramaniam and S Sheriff
Department of Surgery, University of Cincinnati Medical Center, Ohio 45267.

Neuropeptide Y (NPY), a hexatriacontapeptide amide, is present in high concentrations in the mammalian heart. Specific receptors of NPY in rat cardiac ventricular membranes have been characterized recently in our laboratory. Structure-activity studies with selected partial sequences of NPY revealed that NPY(18-36) inhibited the binding of 125I-NPY to rat cardiac ventricular membranes but had no effect on the cardiac adenylate cyclase activity. NPY, as previously reported, inhibited the cardiac adenylate cyclase activity. These observations suggested that NPY (18-36) may be an antagonist of NPY in cardiac membranes. Consistent with this observation, the presence of NPY (18-36) (1 microM) shifted the inhibitory adenylate cyclase activity dose-response curve of NPY to the right in a parallel fashion. Furthermore, NPY(18- 36) (1 microM) completely abolished the effect of NPY (10 nM) that alone caused 80% of the maximum inhibition of adenylate cyclase activity. These findings confirm that NPY(18-36) is a competitive antagonist of NPY in rat cardiac ventricular membranes. NPY cardiac receptor antagonist, NPY(18-36), or analogs based on this sequence may have potential clinical application, since NPY has been implicated in the pathophysiology of congestive heart failure.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Goumain, T. Voisin, A.-M. Lorinet, R. Ducroc, A. Tsocas, C. Roze, P. Rouet-Benzineb, H. Herzog, A. Balasubramaniam, and M. Laburthe The Peptide YY-Preferring Receptor Mediating Inhibition of Small Intestinal Secretion Is a Peripheral Y2 Receptor: Pharmacological Evidence and Molecular Cloning Mol. Pharmacol., July 1, 2001; 60(1): 124 - 134. [Abstract] [Full Text]

				H. X. Wang, M. J. Davis, M. A. S. Rajanayagam, S. J. Potocnik, and M. A. Hill Myogenic reactivity of rat epineurial arterioles: potential role in local vasoregulatory events Am J Physiol Heart Circ Physiol, July 1, 1999; 277(1): H144 - H151. [Abstract] [Full Text] [PDF]

				S. Sheriff, William. T. Chance, Josef. E. Fischer, and A. Balasubramaniam Neuropeptide Y Treatment and Food Deprivation Increase Cyclic AMP Response Element-Binding in Rat Hypothalamus Mol. Pharmacol., April 1, 1997; 51(4): 597 - 604. [Abstract] [Full Text]